---

$23.65

+0.6850 ( +2.98% ) 0.1K

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-05-01	Sale	-4166.00	Okazaki Jason A
2024-05-01	Sale	-3333.00	White Nicole S
2024-05-01	Sale	-3333.00	Delaney William E IV
2024-04-02	Sale	-1206.00	McHutchison John G
2024-04-02	Sale	-850.00	Bjorkquist Jeanette M
2024-04-02	Sale	-197.00	White Nicole S
2024-04-02	Sale	-20000.00	Delaney William E IV
2024-04-02	Sale	-354.00	Okazaki Jason A
2024-03-29	Sale	-392.00	Okazaki Jason A
2024-01-19	Buy	299994.00	Schornstein Alexander